Logotype for Oscar Health Inc

Oscar Health (OSCR) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Oscar Health Inc

Q2 2026 earnings summary

7 Aug, 2026

Executive summary

  • Achieved record profitability in the first half of 2026, with $1.1 billion in earnings from operations and $1 billion in net income, prompting an increase in full-year guidance.

  • Second quarter revenue grew 70% year-over-year to $4.88 billion, with first half revenue at $9.53 billion, driven by higher membership and rate increases.

  • Membership reached approximately 3.0 million as of June 30, 2026, up 46% year-over-year, reflecting strong open enrollment growth and retention.

  • Technology and AI initiatives drove operational efficiencies, supporting margin expansion and cost control.

  • Strong operating performance driven by disciplined pricing, scalable technology, and consumer-focused products.

Financial highlights

  • Premium revenue rose 71% to $4.79 billion for Q2 2026; investment income increased 57% to $84.8 million.

  • Medical loss ratio (MLR) improved to 79.2% for Q2 2026 from 91.1% in Q2 2025, aided by favorable reserve development and pricing discipline.

  • SG&A expense ratio hit a record low of 14.2%, a 450 basis point improvement year-over-year.

  • Earnings from operations were $389 million in Q2, a $619 million year-over-year increase; net income was $362 million, up $590 million.

  • Adjusted EBITDA reached $415 million in Q2 2026, compared to a loss of $199.4 million in Q2 2025.

Outlook and guidance

  • Raised full-year 2026 earnings from operations guidance to $500–$700 million, up $250 million from prior outlook.

  • Full-year revenue expected at $18.7–$19 billion; MLR guidance improved to 81.5%–82.5% (90 bps better at midpoint).

  • SG&A expense ratio guidance improved to 15.6%–16.1%; adjusted EBITDA expected to run $115 million above earnings from operations.

  • Management expects continued regulatory and market volatility due to changes in ACA subsidies, program integrity rules, and new tariffs on pharmaceuticals.

  • Outlook reflects strong first-half performance, favorable prior period development, and positive market morbidity trends.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more